Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1288469/000128846921000100/mxl-20210331.htm
July 2022
June 2022
June 2022
May 2022
May 2022
February 2022
November 2021
October 2021
July 2021
June 2021
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1288469/000128846921000100/mxl-20210331.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Maxlinear Inc.
Maxlinear Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More![]()
36 Table of Contents The following table sets forth our consolidated statement of operations data as a percentage of net revenue for the periods indicated: Three Months Ended March 31, 2021 2020 Net revenue 100 % 100 % Cost of net revenue 47 50 Gross profit 53 50 Operating expenses: Research and development 30 41 Selling, general and administrative 17 40 Impairment losses - - Restructuring charges 1 1 Total operating expenses 49 82 Income (loss) from operations 5 (32) Total interest and other income (expense), net (2) (3) Income (loss) before income taxes 3 (36) Income tax provision (benefit) 1 (11) Net income (loss) 2 % (25) % Net Revenue _______________ (1) Our net revenues by market categories were revised during 2020 to align with changing end-market conditions, our current business priorities, as well as spending requirements and growth opportunities in the four categories.
Research and development expense includes personnel-related expenses, including stock-based compensation, new product engineering mask costs, prototype integrated circuit packaging and test costs, computer-aided design software license costs, intellectual property license costs, reference design development costs, development testing and evaluation costs, depreciation expense and allocated occupancy costs.
Based upon our review of all positive and negative evidence, we continue to have a valuation allowance on state deferred tax assets, certain federal deferred tax assets, and certain foreign deferred tax assets in jurisdictions where we have cumulative losses or otherwise are not expected to utilize certain tax attributes.
In October 2020, the FASB issued ASU No. 2020-10 Codification Improvements, to make incremental improvements to GAAP and address stakeholder suggestions, including, among other things, clarifying that the requirement to provide comparative information in the financial statements extends to the corresponding disclosures section.
Primarily because of our Singapore net operating losses and our full valuation allowance in Singapore, we do not believe the incentives will have a material impact on our income tax position in the year ending December 31, 2021.
Gross profit percentage improved for...Read more
The increase in broadband net...Read more
Selling, general and administrative expense...Read more
Recent Developments On February 23,...Read more
The increase in industrial and...Read more
The increase in infrastructure revenues...Read more
Our cash and cash equivalents...Read more
The incremental term loan of...Read more
The incremental term loan facility...Read more
Cash proceeds from debt and...Read more
The increase in connectivity revenue...Read more
Further, global financial markets reacted...Read more
In addition, the operating results...Read more
Once one of our products...Read more
Factors that could cause or...Read more
We currently expect that gross...Read more
The increase was primarily due...Read more
Our ability to achieve revenue...Read more
Net revenue increased $147.3 million...Read more
We expect our research and...Read more
As a result, our solutions...Read more
The initial term loan facility...Read more
In addition, the NanoSemi stockholders...Read more
Heightened volatility, global supply shortages,...Read more
Further, due to heightened volatility...Read more
Net cash used in financing...Read more
In addition, our proprietary CMOS-based...Read more
There were increases in personnel...Read more
The income tax provision for...Read more
The amendments in this update...Read more
The amendments in this update...Read more
Restructuring charges for the three...Read more
35 Table of Contents Recently...Read more
Our primary uses of cash...Read more
Additional funds may not be...Read more
Our contractual obligations including long-term...Read more
However, a sudden increase in...Read more
The remaining change included a...Read more
Examples of such devices include...Read more
Our cash and cash equivalents...Read more
To protect the health and...Read more
The increase was primarily driven...Read more
Net cash provided by financing...Read more
We continue to maintain a...Read more
Income Tax Provision (Benefit) 39...Read more
The outstanding principal on the...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Maxlinear Inc provided additional information to their SEC Filing as exhibits
Ticker: MXL
CIK: 1288469
Form Type: 10-Q Quarterly Report
Accession Number: 0001288469-21-000100
Submitted to the SEC: Wed Apr 28 2021 4:08:17 PM EST
Accepted by the SEC: Wed Apr 28 2021
Period: Wednesday, March 31, 2021
Industry: Semiconductors And Related Devices